Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q2 FY27 Earnings Presentation
30 slides from Jagsonpal Pharmaceuticals's earnings presentation, Oct 28, 2026
Slide 1: Exchange filing cover letter for results press release
October 28, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code
Slide 2: Jagsonpal announces H1 and Q2 FY27 results
Jagsonpal announces H1 and Q2 FY27 results Q2FY27 Consolidated revenue grew by 29% to ₹964 Mn, 9.3% on standalone basis Standalone H1FY27 EBITDA & PAT up 11.3% and 10.3% respectively | Cash ₹1,347 Mn Two New Acquisitions, on track for the ₹5,000 Mn revenue 2028 mission Gurugram, October 28, 2026 (NS
Slide 3: Inorganic Scale-up and Management Commentary
Inorganic Scale-up Aequitas Healthcare (85% stake; ₹208 Mn all-cash; FY26 revenue ₹533 Mn) was consolidated from Q2, opening the hospital channel with 1,000+ hospitals. The Group Pharma Wellness Portfolio, was completed on 1st October 2026, strengthening the Wellness portfolio and will compliment gr
Slide 4: Q2 & H1 – Performance Highlights: Acceleration in Play
Jagsonpal Pharmaceuticals Limited Q2 & H1 – Performance Highlights ACCELERATION IN PLAY • Organic momentum • Inorganic skill • Strategic reset • Financial strength 2 8 th O c t o b e r 2 0 2 6
Slide 5: Safe Harbor
DISCLAIMER Safe Harbor This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance.
Slide 6: A quarter of building, ahead of a year of acceleration
MANAGING DIRECTOR’S MESSAGE A quarter of building, ahead of a year of acceleration “ In Q2FY27, our focus was to build the platform for our next leg of growth. While our core business grew 9.3% on a like-for-like basis with a 70 bps gross margin expansion, the consolidated revenue stood at ₹964 mill
Slide 7: Q2 & H1FY27 performance
Q2 & H1FY27 performance Accelerating growth, gross margin expansion and a calibrated step-up in investment
Slide 8: Business Updates - Acceleration on every front
THE LAST SIX MONTHS Business Updates - Acceleration on every front Organic, inorganic, strategic and financial levers are all moving at once Organic Inorganic • ~9.3% growth in Q2; H1 sales up 9.0% • Aequitas Healthcare consolidated from Q2 • Q2 Gross margin up 10.5%, up 70 bps • Completed acquisiti
Slide 9: Pillars for the next leg of growth
WHERE THE INVESTMENT WENT Pillars for the next leg of growth Investments front-ended in Q2; the benefits to reflect from Q3 Hospital team Aequitas reset Group Pharma’s Wellness Portfolio Hospital team strengthened to Supply chain streamlined, overall Marketing inputs and foundation planning cross-se
Slide 10: Transformation to a multi-channel specialty platform
THEN VS NOW Transformation to a multi-channel specialty platform Key strategic developments YTD FY27 YTD FY2026 YTD FY2027 Acquired businesses 1 Yash Pharma business 3 + Aequitas Healthcare and the Group Pharma wellness portfolio Hospital channel None No institutional presence 1,000+ hospitals, plus
Slide 11: Power brands: niche leaders driving growth
BRAND FRANCHISE Power brands: niche leaders driving growth Top 10 brands make up ~58% of revenue, and 9 of them rank in the top 5 of their markets Brand MAT (₹ Cr) Molecule MAT (₹ Cr) Rank Brand Sep'26 Sep'25 Gr% Sep'26 Sep'25 Gr% 1 Indocap 40.4 38.7 4.5% 54.1 51.5 5.0% 2 Maintane Inj. 35.9 26.8 33.
Slide 12: Q2 & H1FY27: Strong growth across Revenue, EBITDA and PAT
YoY HIGHLIGHTS Q2 & H1FY27: Strong growth across Revenue, EBITDA and PAT Profit grew faster than sales; EBITDA held broadly flat as we invested ahead of growth All values in ₹ Mn Revenue from Operations Gross Profit & Margin EBITDA* & Margin PAT & Margin ■ Q2FY26 ■ Q2FY27 ▲ +5 Mn (+2.5%) ▲ +0.1 Mn (
Slide 13: Income statement (Standalone)
STANDALONE FINANCIALS Income statement All values in ₹ Mn Particulars Q2FY27 Q2FY26 YoY % H1FY27 H1FY26 YoY % Revenue from Operations 814 745 9.3% 1,636 1,501 9.0% Q2 Highlights Total Expenses (629) (564) 11.5% (1,261) (1,163) 8.4% EBITDA* 185 180 2.5% 375 337 11.3% • Revenue growth of ~9.3% YoY EBI
Slide 14: Key Balance Sheet Items (Standalone)
STANDALONE FINANCIALS Key Balance Sheet Items All values in ₹ Mn Particulars 30-Sep-26 30-Jun-26 30-Sep-25 Q2 Highlights Shareholders Funds 2,438 2,548 2,528 • Aequitas acquired for an all-cash Tangible Assets 6 6 6 consideration of ₹208 Mn • Enhanced dividend payout of ₹264 Mn Investments in Subsid
Slide 15: Income statement (Consolidated)
CONSOLIDATED FINANCIALS Income statement All values in ₹ Mn Particulars Q2FY27 H1FY27 Revenue from Operations 964 1,786 Total Expenses (778) (1,406) EBITDA* 186 377 EBITDA Margin* 19.3% 21.1% Other Income 23 51 ESOP Cost (17) (35) Depreciation (22) (43) EBIT 169 349 EBIT Margin 17.6% 19.5% Finance C
Slide 16: Key Balance Sheet Items (Consolidated)
CONSOLIDATED FINANCIALS Key Balance Sheet Items All values in ₹ Mn Particulars 30-Sep-26 Shareholders Funds 2,407 Non-Controlling Interest 36 Tangible Assets 6 Intangibles 977 Right of Use Assets 68 Financial Assets (Cash & Equivalents) 1,360 Other Non-Current Assets (Net) 147 Lease liabilities 83 N
Slide 17: Inorganic acceleration
Inorganic acceleration Three acquisitions, three new growth vectors and a clear integration playbook
Slide 18: A proven acquisition engine, now running faster
OUR INORGANIC JOURNEY A proven acquisition engine, now running faster A strong balance sheet, a proven playbook and a clear pipeline May 2024 July 2026 October 2026 Next + New therapy areas Hospital channel Wellness entry Disciplined pipeline Entry into Dermatology & Paediatrics; 1,000+ hospitals an
Slide 19: Aequitas: strategic reset in first quarter
AEQUITAS HEALTHCARE • ACQUIRED JULY 2026 Aequitas: strategic reset in first quarter Streamlined costs; focus on margins; impact to be visible from Q4 Value Creation Planned in Line Supply chain streamlined Overall cost brought down Procurement and distribution consolidated Duplicate overheads remove
Slide 20: Wellness Portfolio of Group Pharma: Ready Integration Playbook
Group Pharma Wellness Portfolio • ACQUIRED OCT 2026 Wellness Portfolio of Group Pharma : Ready Integration Playbook Deepens wellness portfolio with significant growth opportunity and PAN India presence Value Creation Opportunities Integrated within the largest Deeper penetration in key markets: divi
Slide 21: Yash Pharma: proof that our integration playbook works
ACQUISITION • MAY 2024 • FULLY INTEGRATED Yash Pharma: proof that our integration playbook works Internal-accruals-led acquisition that took us into Dermatology and Paediatrics EBITDA margin of the acquired business ~10% ~22% 5 decades 250+ of experience field strength At acquisition Today • Product
Slide 22: On the road to a ₹5,000 Mn organization
OUR TWO-YEAR MISSION On the road to a ₹5,000 Mn organization Organic growth from core brands and launches along with inorganic growth from Aequitas & the wellness portfolio Revenue trajectory (₹ Mn) Strengthen Women’s Health & Orthopaedics 01 Deepen our strongest categories 5000 Field-force producti
Slide 23: About Jagsonpal
About Jagsonpal A legacy of quality and trust since 1964
Slide 24: A legacy of 'Quality and Trust' since 1964
WHO WE ARE A legacy of ‘Quality and Trust’ since 1964 A 100% India-centric, asset-light branded-generics company in sub-chronic therapies Quality culture Power brand portfolio CMOs fully compliant with WHO-GMP and Top 10 brands contribute 58%; 9 brands ISO 9001:2015, with 300+ quality checks rank in
Slide 25: Strong presence in key therapies
THERAPY LEADERSHIP Strong presence in key therapies Ranked #8 in corporate CVM (as per CMARC RPM) Gynaecology Orthopaedics Dermatology Wellness Portfolio #7 ~90% #2 ~80% #30 ~40% With integration now complete, focused CVM rank doctor coverage CVM rank doctor coverage CVM rank doctor coverage executi
Slide 26: Consistent operational excellence, FY22–FY26
TRACK RECORD Consistent operational excellence, FY22–FY26 PAT 2.4x, cash balance 2.5x and free cash flow 8x over four years Revenue (₹ Mn) CAGR 7.2% Gross profit (₹ Mn)* CAGR 9.1% Op. EBITDA (₹ Mn)* CAGR 24.9% 2,872 1,829 609 2,176 1,286 250 FY22 FY26 FY22 FY26 FY22 FY26 Operational PAT (₹ Mn) CAGR
Slide 27: Excellence across every parameter
CAPITAL EFFICIENCY & RETURNS Excellence across every parameter Working capital down 69%, dividend payout up 2.5x, PAT margin up 700 bps and FCF conversion at 92% Margin expansion, FY22 vs FY26 (%) NWC days NWC as % of sales FY22 → FY26 FY22 → FY26 64 59 → 11 16.1% → 3.8% 59 −69% Leaner FCF conversio
Slide 28: A high-impact, asset-light model
HOW WE OPERATE A high-impact, asset-light model Capital-intensive activities are outsourced, so growth needs little capital 01 02 03 04 Ideation Research & development Contract manufacturing Pan-India distribution In-house ideation of innovative drug Partnerships with leading CDMO players Partnershi
Slide 29: MySakhi: where business meets social impact
CSR HIGHLIGHTS MySakhi: where business meets social impact Empowering women and communities through health, hygiene and relief Sanitation Awareness Relief A dedicated platform offering educational resources, 20 24 Assam & Punjab health tools and community support focused on women’s health, with self
Slide 30: Thank you
Thank you JAGSONPAL PHARMACEUTICALS LTD. Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi – 110020 INVESTOR RELATIONS Soumya Chhajed soumya@goindiaadvisors.com +91 8619707750
Jagsonpal Pharmaceuticals — Q2 FY27 Earnings Presentation on 6ix